2-methoxy-4-[2-(2-methoxyethyl)-1H-imidazol-5-yl]aniline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-methoxy-4-[2-(2-methoxyethyl)-1H-imidazol-5-yl]aniline
• 化学式: C₁₃H₁₇N₃O₂
• 分子量: 247.29
• InChiKey: IXOVMQABAZJTAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  73.2
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• [EN] PHARMACOLOGICALLY ACTIVE COMPOUNDS<br/>[FR] COMPOSÉS PHARMACOLOGIQUEMENT ACTIFS
  申请人：CANCER REC TECH LTD

  公开号：WO2014037751A1

  公开（公告）日：2014-03-13

  The present invention relates to compounds of formula (II) wherein X, Y, R2, R3, R4 and Ar are all as defined herein. The compounds of the present invention are known to inhibit the spindle checkpoint function of Monospindle 1 (Mps1 – also known as TTK) kinases either directly or indirectly via interaction with the Mps1 kinase itself. In particular, the present invention relates to the use of these compounds as therapeutic agents for the treatment and/or prevention of proliferative diseases, such as cancer. The present invention also relates to processes for the preparation of these compounds, and to pharmaceutical compositions comprising them.

  本发明涉及式（II）的化合物，其中X、Y、R2、R3、R4和Ar均如本文所定义。本发明的化合物已知能够通过直接或间接与Mps1激酶相互作用来抑制单丝粒体1（Mps1-也被称为TTK）激酶的纺锤体检查点功能。具体地，本发明涉及将这些化合物用作治疗和/或预防增生性疾病，如癌症的治疗剂。本发明还涉及这些化合物的制备方法，以及包含它们的药物组合物。
• PHARMACOLOGICALLY ACTIVE COMPOUNDS
  申请人：Cancer Research Technology Ltd

  公开号：EP2892890A1

  公开（公告）日：2015-07-15